Physician profile
Daniel Einhorn
NPI 1275525776
$578,406.04
in general payments reported to CMS, 2019-2025
25 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $143K · 2021: $215K · 2022: $84K · 2023: $4,944 · 2024: $98.88 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,044 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,550 · Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,044.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,550.00 |
| Food and Beverage | $666.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $170,700.54 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $139,080.05 | 2019-2025 | |
| Abbott Laboratories | $83,868.67 | 2019-2023 | Freestyle Libre 3 |
| Intuity Medical INC | $57,812.30 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Corcept Therapeutics | $45,193.49 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $23,608.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,491.76 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $14,565.00 | 2019-2020 | |
| Eli Lilly and Company | $5,250.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $5,070.17 | 2019-2021 | |
| Vistapharm, INC. | $4,250.00 | 2021 | |
| Senseonics, Incorporated | $3,523.00 | 2019-2020 | |
| Lifescan, INC. | $2,732.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $2,642.05 | 2019-2021 | |
| Zealand Pharma US, INC. | $2,388.52 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,535.00 | 2021 | |
| Esperion Therapeutics, INC. | $283.87 | 2021-2022 | |
| Amgen INC. | $154.80 | 2019-2020 | |
| Janssen Global Services, LLC | $66.94 | 2019 | |
| Mannkind Corporation | $59.40 | 2019 | |
| Insulet Corporation | $40.76 | 2019-2020 | |
| Horizon Therapeutics Plc | $40.07 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.04 | 2021 | |
| Gilead Sciences, INC. | $16.16 | 2019 | |
| Dexcom, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Einhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.